Look at Whole Prescribing Facts OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed just after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after three or even more lines of systemic therapy that features autologous